Lexeo Therapeutics, Inc. Common Stock
NASDAQ:LXEO · NASDAQ Global Market
-$0.05 today
Vol 1.08M · Avg 0.86M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-40.5%
avg 8.9%
ROIC
-42.9%
avg -50.6%
ROA
-37.2%
avg -44.5%
Analysis
ROA is currently the strongest return metric at -37.2% versus its period average of -44.5%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Jose Manuel Otero | Chief Operating Officer | $2.99M | — | 47 | $130,088.00 | 0.17% |
Eric Adler | Advisor | $2.71M | — | 52 | $72,646.00 | 0.09% |
R. Nolan Townsend | Chief Executive Officer & Director | $991,470.00 | — | 45 | $336,764.00 | 0.43% |
Louis Tamayo | Chief Financial Officer & Principal Accounting Officer | $638,897.00 | — | 49 | $226,665.00 | 0.29% |
Ronald G. Crystal | Co-Founder, Chief Scientific Advisor & Member of Scientific Advisory Board | — | — | — | — | — |
Jordan Baumhardt | Vice President of Corporate Development | — | — | — | — | — |
Keith Wonnacott | Senior Vice President of Regulatory Affairs | — | — | — | — | — |
Narinder Bhalla FACC FSCAI | Chief Medical Officer | — | — | 62 | $297,000.00 | 0.38% |
Leslie DiRisio | Senior Vice President of Development Operations | — | — | — | — | — |
Ryan McHenry | Vice President & Corporate Controller | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
26
$725,171.42
Net Sentiment
$725,171.42
Net selling
Most Active
Otero Jose Manuel
7 transactions
1–10 of 26
Analysis
Insiders reported 0 buys worth $0.00 and 26 sells worth $725,171.42 over the last 12 months. That adds up to net selling of $725,171.42. Otero Jose Manuel was the most active insider with 7 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Capricor Therapeutics, Inc.
NASDAQ:CAPR
$1.29B
Contineum Therapeutics, Inc. Class A Common Stock
NASDAQ:CTNM
$438.92M
DBV Technologies S.A.
NASDAQ:DBVT
$385.73M
Kyverna Therapeutics, Inc.
NASDAQ:KYTX
$347.71M
Vanda Pharmaceuticals Inc.
NASDAQ:VNDA
$346.08M
Amarin Corporation plc
NASDAQ:AMRN
$334.13M
Silence Therapeutics plc
NASDAQ:SLN
$324.26M
Larimar Therapeutics, Inc.
NASDAQ:LRMR
$299.95M
Voyager Therapeutics, Inc.
NASDAQ:VYGR
$223.26M
Mereo BioPharma Group plc
NASDAQ:MREO
$50.90M
Who manages LXEO?
Lexeo Therapeutics, Inc. Common Stock (LXEO) lists 10 active executives. The top listed executive is R. Nolan Townsend, Chief Executive Officer & Director.
Are LXEO insiders buying or selling?
Recent insider activity shows net buying of $26.04M.
Explore More
Continue the stock analysis
Jump to another research area for this company.